(OSUR) OraSure Technologies - Ratings and Ratios
Home Hiv Test, Rapid Drug Test, Lab Sample Collection Kit
OSUR EPS (Earnings per Share)
OSUR Revenue
Description: OSUR OraSure Technologies
OraSure Technologies Inc (NASDAQ:OSUR) is a diagnostics company that develops, manufactures, and markets various diagnostic products, including rapid tests for infectious diseases such as HIV, HCV, and Ebola, as well as specimen collection devices and genomic products for genetic testing. The companys product portfolio is diverse, with applications in clinical laboratories, hospitals, clinics, and public health organizations, among others.
From a business perspective, OraSure Technologies has a strong presence in the healthcare diagnostics market, with a range of products that cater to different customer segments. The companys focus on rapid diagnostic tests and specimen collection devices positions it well in the growing market for point-of-care diagnostics. Key performance indicators (KPIs) to watch include revenue growth, gross margin, and operating expenses as a percentage of revenue. For instance, the companys ability to maintain a high gross margin (> 60%) would indicate its pricing power and competitive advantage. Additionally, OraSures research and development (R&D) expenses as a percentage of revenue (~ 15-20%) would suggest its commitment to innovation and new product development.
The companys product pipeline, including the development of a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae, is also an important factor to consider. A successful launch of this product could drive future revenue growth and expand OraSures presence in the sexually transmitted infection (STI) diagnostics market. Other KPIs to monitor include the companys cash position, debt-to-equity ratio, and return on assets (ROA). A strong cash position and low debt-to-equity ratio would indicate OraSures financial stability and ability to invest in growth initiatives.
OraSures market presence and product offerings also expose it to various risks, including regulatory changes, competition from other diagnostics companies, and fluctuations in demand for its products. As a trading analyst, it is essential to monitor these risks and assess their potential impact on the companys financial performance and stock price. Key metrics to track include the companys market share, customer concentration, and product diversification.
OSUR Stock Overview
| Market Cap in USD | 236m |
| Sub-Industry | Health Care Supplies |
| IPO / Inception | 1986-11-12 |
OSUR Stock Ratings
| Growth Rating | -54.8% |
| Fundamental | 31.5% |
| Dividend Rating | 0.05% |
| Return 12m vs S&P 500 | -36.8% |
| Analyst Rating | 3.50 of 5 |
OSUR Dividends
Currently no dividends paidOSUR Growth Ratios
| Growth Correlation 3m | 32.5% |
| Growth Correlation 12m | -82.1% |
| Growth Correlation 5y | -79.2% |
| CAGR 5y | -4.56% |
| CAGR/Max DD 3y | -0.06 |
| CAGR/Mean DD 3y | -0.13 |
| Sharpe Ratio 12m | -1.24 |
| Alpha | 0.18 |
| Beta | 0.384 |
| Volatility | 45.39% |
| Current Volume | 425.3k |
| Average Volume 20d | 470.5k |
| Stop Loss | 3.1 (-5.8%) |
| Signal | 0.07 |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-51.0m TTM) > 0 and > 6% of Revenue (6% = 2.32m TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA -10.25pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -108.7% (prev 117.8%; Δ -226.5pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.04 (>3.0%) and CFO -17.2m > Net Income -51.0m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 0.01 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (74.5m) change vs 12m ago 0.52% (target <= -2.0% for YES) |
| Gross Margin -175.2% (prev 47.47%; Δ -222.7pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 8.49% (prev 58.66%; Δ -50.17pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM) |
Altman Z'' -5.03
| (A) -0.09 = (Total Current Assets 293.9k - Total Current Liabilities 42.4m) / Total Assets 445.0m |
| (B) -0.31 = Retained Earnings (Balance) -139.2m / Total Assets 445.0m |
| (C) -0.12 = EBIT TTM -56.7m / Avg Total Assets 455.7m |
| (D) -2.43 = Book Value of Equity -156.5m / Total Liabilities 64.3m |
| Total Rating: -5.03 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 31.46
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield 4.69% = 2.34 |
| 3. FCF Margin 31.44% = 7.50 |
| 4. Debt/Equity 0.06 = 2.50 |
| 5. Debt/Ebitda -0.53 = -2.50 |
| 6. ROIC - WACC (= -21.60)% = -12.50 |
| 7. RoE -12.66% = -2.11 |
| 8. Rev. Trend -77.66% = -5.82 |
| 9. EPS Trend -79.01% = -3.95 |
What is the price of OSUR shares?
Over the past week, the price has changed by +0.92%, over one month by +17.50%, over three months by +17.08% and over the past year by -25.06%.
Is OraSure Technologies a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of OSUR is around 2.71 USD . This means that OSUR is currently overvalued and has a potential downside of -17.63%.
Is OSUR a buy, sell or hold?
- Strong Buy: 1
- Buy: 0
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the OSUR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6 | 82.4% |
| Analysts Target Price | 6 | 82.4% |
| ValueRay Target Price | 3 | -9.7% |
Last update: 2025-09-18 04:39
OSUR Fundamental Data Overview
CCE Cash And Equivalents = 234.6k USD (Cash And Short Term Investments, last quarter)
P/S = 1.7
P/B = 0.6186
P/EG = 2.3
Beta = 0.438
Revenue TTM = 38.7m USD
EBIT TTM = -56.7m USD
EBITDA TTM = -45.8m USD
Long Term Debt = 22.0m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 2.15m USD (from shortTermDebt, last quarter)
Debt = 24.1m USD (Calculated: Short Term 2.15m + Long Term 22.0m)
Net Debt = -234.6k USD (from netDebt column, last quarter)
Enterprise Value = 259.4m USD (235.5m + Debt 24.1m - CCE 234.6k)
Interest Coverage Ratio = unknown (Ebit TTM -56.7m / Interest Expense TTM 0.0)
FCF Yield = 4.69% (FCF TTM 12.2m / Enterprise Value 259.4m)
FCF Margin = 31.44% (FCF TTM 12.2m / Revenue TTM 38.7m)
Net Margin = -132.0% (Net Income TTM -51.0m / Revenue TTM 38.7m)
Gross Margin = -175.2% ((Revenue TTM 38.7m - Cost of Revenue TTM 106.4m) / Revenue TTM)
Tobins Q-Ratio = -1.66 (set to none) (Enterprise Value 259.4m / Book Value Of Equity -156.5m)
Interest Expense / Debt = 11.09% (Interest Expense 2.67m / Debt 24.1m)
Taxrate = 21.0% (US default)
NOPAT = -56.7m (EBIT -56.7m, no tax applied on loss)
Current Ratio = 0.01 (Total Current Assets 293.9k / Total Current Liabilities 42.4m)
Debt / Equity = 0.06 (Debt 24.1m / last Quarter total Stockholder Equity 380.7m)
Debt / EBITDA = -0.53 (Net Debt -234.6k / EBITDA -45.8m)
Debt / FCF = 1.98 (Debt 24.1m / FCF TTM 12.2m)
Total Stockholder Equity = 403.2m (last 4 quarters mean)
RoA = -11.47% (Net Income -51.0m, Total Assets 445.0m )
RoE = -12.66% (Net Income TTM -51.0m / Total Stockholder Equity 403.2m)
RoCE = -13.33% (Ebit -56.7m / (Equity 403.2m + L.T.Debt 22.0m))
RoIC = -14.05% (NOPAT -56.7m / Invested Capital 403.2m)
WACC = 7.55% (E(235.5m)/V(259.6m) * Re(7.43%)) + (D(24.1m)/V(259.6m) * Rd(11.09%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 60.61 | Cagr: 0.22%
Discount Rate = 7.43% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 70.46% ; FCFE base≈31.5m ; Y1≈20.7m ; Y5≈9.46m
Fair Price DCF = 2.54 (DCF Value 186.0m / Shares Outstanding 73.1m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -79.01 | EPS CAGR: -67.85% | SUE: -0.20 | # QB: 0
Revenue Correlation: -77.66 | Revenue CAGR: -94.97% | SUE: N/A | # QB: None
Additional Sources for OSUR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle